Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea

ClinicalTrials.gov ID: NCT00329459

Public ClinicalTrials.gov record NCT00329459. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Single Migraine Attack, Placebo -Controlled, Patallel-group Multicenter Study to Evaluate the Efficacy and Tolerability or Trexima (Sumatriptan Succinate/Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea

Study identification

NCT ID
NCT00329459
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
320 participants

Conditions and interventions

Interventions

  • sumatriptan succinate/naproxen sodium Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2006
Primary completion
Oct 31, 2006
Completion
Oct 31, 2006
Last update posted
Oct 23, 2016

2006

United States locations

U.S. sites
34
U.S. states
22
U.S. cities
34
Facility City State ZIP Site status
GSK Investigational Site Mesa Arizona 85201
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Fair Oaks California 95628
GSK Investigational Site Newport Beach California 92660
GSK Investigational Site San Diego California 92128
GSK Investigational Site San Francisco California 94102
GSK Investigational Site Stamford Connecticut 06902
GSK Investigational Site Fort Lauderdale Florida 33328
GSK Investigational Site Miami Florida 33173
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Milford Massachusetts 01757
GSK Investigational Site North Dartmouth Massachusetts 02747
GSK Investigational Site Detroit Michigan 48201
GSK Investigational Site Springfield Missouri 65804
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Moorestown New Jersey 08057
GSK Investigational Site Albuquerque New Mexico 87102
GSK Investigational Site Albany New York 12206
GSK Investigational Site Plainview New York 11803
GSK Investigational Site Rochester New York 14609
GSK Investigational Site Greensboro North Carolina 27401
GSK Investigational Site Cleveland Ohio 44195
GSK Investigational Site Independence Ohio 44131
GSK Investigational Site Westerville Ohio 43081
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Greer South Carolina 29651
GSK Investigational Site Memphis Tennessee 38018
GSK Investigational Site Austin Texas 78705
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00329459, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 23, 2016 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00329459 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →